Eli Lilly and Company’s Ebglyss (lebrikizumab) will hit the US market in early October for the treatment of moderate-to-severe atopic dermatitis, competing against Sanofi and Regeneron Pharmaceuticals, Inc.’s mega-blockbuster Dupixent (dupilumab).
Key Takeaways
- Lilly’s Ebglyss (lebrikizumab) will compete for share against Sanofi/Regeneron’s Dupixent in the US after being approved by the FDA for atopic dermatitis.
- Ebglyss will offer once-monthly dosing in the maintenance setting, which could be an advantage over Dupixent’s dosing every two weeks
Ebglyss is launching with similar Phase III efficacy data to Dupixent and with once-monthly maintenance dosing, making it a serious contender to take share from Dupixent, which is the first biologic approved for atopic dermatitis and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?